Explore patient cases in this conversational video series
 |
 |
 |
|
Treatment of 1L Advanced Renal Cell Carcinoma in Patients With Multiple Sites of Metastases |
|
 | | |
|
Dr. Robert Alter and Dr. Arash Rezazadeh share data from the CheckMate-9ER trial and discuss their considerations for treatment of 1L aRCC with CABOMETYX + OPDIVO. |
|
| | |
|
|
Treating Patients With 1L Advanced Renal Cell Carcinoma, Including Patient QOL Considerations |
|
 | | |
|
Watch a discussion with Dr. Robert Alter and Dr. Arash Rezazadeh as they evaluate treatment with CABOMETYX® (cabozantinib) + OPDIVO® (nivolumab) for patients with 1L aRCC. |
|
| |
| |
|
Treatment Decisions and Dose Management |
|
 | | |
|
Hear Dr. Kirollos Hanna and Dr. Joshua Strauss discuss treatment decisions when initiating CABOMETYX and dose management to help optimize outcomes. |
|
| |
| |
| |
|
INDICATION |
|
CABOMETYX® (cabozantinib), in combination with nivolumab, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). |
|
IMPORTANT SAFETY INFORMATION |
|
WARNINGS AND PRECAUTIONS |
|
The full Prescribing Information for CABOMETYX includes Warnings and Precautions for: |
|
• |
Hemorrhage |
|
• |
Perforations and Fistulas |
|
• |
Thrombotic Events |
|
• |
Hypertension and Hypertensive Crises |
|
• |
Diarrhea |
|
• |
Palmar-Plantar Erythrodysesthesia (PPE) |
|
• |
Hepatotoxicity |
|
• |
Adrenal Insufficiency |
|
• |
Proteinuria |
|
• |
Osteonecrosis of the Jaw |
|
• |
Impaired Wound Healing |
|
• |
Reversible Posterior Leukoencephalopathy Syndrome |
|
• |
Thyroid Dysfunction |
|
• |
Hypocalcemia |
|
• |
Embryo-Fetal Toxicity | |
|
ADVERSE REACTIONS |
|
The most common (≥20%) adverse reactions are: |
|
CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. |
|
Please see full Prescribing Information for additional important safety information. |
|
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088. |
|
If you would like more information about CABOMETYX, please visit CABOMETYXhcp.com. |
|
This email is intended for US healthcare professionals only. |
|
This promotional email is brought to you by Exelixis. | |
|
|
| |
|
|
This content is sponsored by Exelixis, and ION Oncology Practice Network has not independently reviewed or verified the information provided by Exelixis. | | |
